Keros Therapeutics' (KROS) "Buy" Rating Reaffirmed at HC Wainwright

Keros Therapeutics (NASDAQ:KROS - Get Free Report)'s stock had its "buy" rating reaffirmed by equities research analysts at HC Wainwright in a report issued on Thursday, Benzinga reports. They currently have a $100.00 price objective on the stock. HC Wainwright's price objective indicates a potential upside of 73.61% from the company's previous close.

Several other research firms have also issued reports on KROS. Truist Financial restated a "buy" rating and set a $100.00 price target on shares of Keros Therapeutics in a report on Wednesday, March 13th. Wedbush reaffirmed an "outperform" rating and set a $86.00 price target on shares of Keros Therapeutics in a research report on Thursday, February 29th. William Blair reiterated an "outperform" rating on shares of Keros Therapeutics in a research note on Wednesday, February 21st. Finally, Piper Sandler restated an "overweight" rating and set a $105.00 price target on shares of Keros Therapeutics in a research report on Wednesday, March 27th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $86.00.

Keros Therapeutics Stock Down 1.1 %

NASDAQ:KROS traded down $0.64 during mid-day trading on Thursday, reaching $57.60. 195,613 shares of the company were exchanged, compared to its average volume of 402,160. Keros Therapeutics has a 12 month low of $27.02 and a 12 month high of $73.00. The company has a fifty day moving average of $62.76 and a 200 day moving average of $49.64. The stock has a market cap of $2.08 billion, a PE ratio of -11.04 and a beta of 1.32.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its earnings results on Wednesday, May 8th. The company reported ($1.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.33) by $0.12. The company had revenue of $0.08 million for the quarter. During the same period in the previous year, the company posted ($1.26) EPS. The business's revenue was down 97.3% compared to the same quarter last year. On average, equities research analysts anticipate that Keros Therapeutics will post -5.11 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Keros Therapeutics by 18.8% in the 3rd quarter. Vanguard Group Inc. now owns 1,406,431 shares of the company's stock worth $44,837,000 after buying an additional 222,652 shares during the period. Braidwell LP grew its stake in shares of Keros Therapeutics by 18.7% in the 3rd quarter. Braidwell LP now owns 1,357,309 shares of the company's stock worth $43,271,000 after buying an additional 213,444 shares during the last quarter. Franklin Resources Inc. increased its position in Keros Therapeutics by 47.9% during the 4th quarter. Franklin Resources Inc. now owns 699,425 shares of the company's stock valued at $27,809,000 after buying an additional 226,674 shares in the last quarter. ADAR1 Capital Management LLC purchased a new position in Keros Therapeutics during the fourth quarter valued at $27,367,000. Finally, CHI Advisors LLC raised its stake in Keros Therapeutics by 1.4% during the third quarter. CHI Advisors LLC now owns 407,633 shares of the company's stock valued at $12,995,000 after buying an additional 5,515 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company's stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.